Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2025-12-26 @ 12:03 AM
Study NCT ID:
NCT05170659
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2022-04-28
First Post:
2021-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access for Relatlimab
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
None
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an expanded access designed to provide access to Relatlimab for eligible participants.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: